Current trends in the treatment of sickle cell anemia

• Authors: Waheed Sakariyau Adio , Francisca Chioma Christopher , Ridwan Olamilekan Adesola , Folorunso Ibikun Mary
• Languages of publication: EN

Abstracts

EN

Sickle cell disease is a set of illnesses characterized by the misshaping and breakdown of red blood cells. Red blood cells twist into a sickle shape in sickle cell disease, an inherited set of illnesses. The cells die early, resulting in a lack of healthy red blood cells (sickle cell anemia), and they might impede blood flow, causing pain (sickle cell crisis). Vernon Mason coined the term "sickle cell anemia" in 1922. SCD is thought to have killed approximately 114,800 individuals worldwide, and it is more common among people whose ancestors lived in tropical and subtropical sub-Saharan Africa, where malaria is or was prevalent. There are several types of SCD, including homozygous HbS and HbS/HbC co-inheritance (usually called HbSC). A genetic mutation causes the condition, which disrupts the iron-rich molecule essential for making blood red and transporting oxygen. SCD has been treated using a variety of approaches. The use of hydroxycarbamide and L-glutamine, blood transfusions, bone marrow transplants, gene therapy, and nutritional supplementation are just a few of them. Gene therapy is the most effective treatment option on the list. The method relies on modifying and reprogramming cells from the patient's own blood cells, as well as genetic engineering, to fix the inborn genetic defect. hydroxyurea, on the other hand, has been shown to change the course of the disease. Finally, if utilized correctly, a combination of available therapeutic medications could greatly improve the disease.

Keywords

EN

Sickle cell anemia; gene therapy; hydroxycarbamide

Discipline

• MEDICINE: MEDICINE

• Publisher: Scientific Publishing House „DARWIN”
• Journal: World News of Natural Sciences
• Year: 2022
• Volume: 43
• Pages: 60-75

Contributors

author

Waheed Sakariyau Adio

• Department of Biochemistry, Faculty of Life Science, Federal University of Technology Minna, Bosso LGA, Niger State, Nigeria

author

Francisca Chioma Christopher

• Department of Biochemistry, Faculty of Life Science, Federal University of Technology Minna, Bosso LGA, Niger State, Nigeria

author

Ridwan Olamilekan Adesola

• Department of Veterinary Medicine, Faculty of Veterinary Medicine, University of Ibadan, Ibadan, Oyo State, Nigeria

author

Folorunso Ibikun Mary

• Federal University of Technology, Akure, Ondo State, Akure, Nigeria

References

• [1] Aidoo, M., Terlouw, D.J., Kolczak, M.S., McElroy, P.D., ter-Kuile, F.O., Kariuki, S., Nahlen, B.L., Lal, A.A., and Udhayakumar, V. (2002). Protective effects of the sickle cell gene against malaria morbidity and mortality. Lancet, 359(9314): 1311–1132
• [2] Almeida, A., and Roberts, I. (2005). Bone involvement in sickle cell disease. British Journal of Haematology, 129(4): 482–490
• [3] American Society of Hematology, (2019). Sickle Cell Disease Family Fact Sheet. Michigan Newborn Screening Program.
• [4] Anie, K.A., and Green, J. (2015). Psychological therapies for sickle cell disease and pain. The Cochrane Database of Systematic Reviews, 5: CD001916
• [5] Ansong, D., Akoto, A.O., Ocloo, D., and Ohene-frempong, K. (2013). Sickle Cell Disease: Management Options and Challenges in Developing Countries. Mediterrean Journal of Hematolology and Infectious Disease, 5: 2013062
• [6] Ballas, S.K. (1998). Sickle cell disease: clinical management. Baillieres Clinical Haematology, 11: 185-214
• [7] Ballas SK, Kesen MR, Goldberg MF, Lutty GA, Dampier C, Osunkwo I, Wang WC, Hoppe C, Hagar W, Darbari DS, Malik P. Beyond the definitions of the phenotypic complications of sickle cell disease: an update on management. ScientificWorld Journal. 2012; 2012: 949535. doi: 10.1100/2012/949535
• [8] Balgir, R.S. (2012). Community expansion and genegeography of sickle cell trait and G6PD-deficiency, and natural selection against malaria: experience from tribal land of India. Cardiovascular & Hematological Agents in Medicinal Chemistry, 10(1): 3–13
• [9] Bookchin, R.M., and Lew, V.L. (1996). Pathophysiology of sickle cell anemia. Hematology and Oncology Clinical North America, 10:1241-1253
• [10] Bunn, H.F. (1997). Pathogenesis and treatment of sickle cell disease. Northern England Journal of Medicine, 337:762-769.
• [11] Capriotti, Ryan. The Efficacy of Structured Repeated Reading as a Method to Increase Reading Fluency. (2016). All Capstone Projects. 179.
• [12] Caughey, M.C., Poole, C., Ataga, K.I., and Hinderliter, A.L. (2015). Estimated pulmonary artery systolic pressure and sickle cell disease: a meta-analysis and systematic review. British Journal of Hematology, 170(3): 416–424
• [13] Centers for Disease Control and Prevention, (2016). Data & Statistics on Sickle Cell Disease. 31 August 2016. Retrieved 13, December 2019.
• [14] Clarke, G.M., and Higgins, T.N. (2000). Laboratory investigation of hemoglobinopathies and thalassemias: review and update. Clinical Chemistry, 46(82): 1284–1290
• [15] Cordeiro, N.J., and Oniyangi, O. (2004). Phytomedicines (medicines derived from plants) for sickle cell disease. Cochrane Database System Review.
• [16] Danaee A, Inusa B, Howard J, Robinson S. Hyperhemolysis in Patients With Hemoglobinopathies: A Single-Center Experience and Review of the Literature. Transfus Med Rev. 2015 Oct; 29(4): 220-30. doi: 10.1016/j.tmrv.2015.06.001
• [17] De-Montalembert, M. (2002). Management of children with sickle cell anemia: A collaborative work. Archive of Pediatric, 9: 1195–1201
• [18] Desai, D. V., & Dhanani, H. (2004). Sickle cell disease: history and origin. The Internet Journal of Hematology, 1(2), 1540
• [19] Dixit, R., Nettem, S., Madan, S.S., Soe, H.H., Abas, A.B., Vance, L.D., and Stover, P.J. (2018). Folate supplementation in people with sickle cell disease. The Cochrane Data Base of Systematic Reviews, 3: CD011130
• [20] Gardner, R.V. (2018). Sickle Cell Disease: Advances in Treatment. Ochsner Journal, 18: 377–389
• [21] Glassberg, J. (2011). Evidence-based management of sickle cell disease in the emergency department. Emergency Medicine Practice, 13(8): 1–20
• [22] Global Burden of Disease, (2015). Global, regional, and national life expectancy, all cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, 388(10053): 1459–1544
• [23] Green, N.S., Fabry, M.E., Kaptue-Noche, L., and Nagel, R.L. (1993). Senegal haplo type is associated with higher HbF than Benin and Cameroon haplo types in African children with sickle cell anemia. American Journal of Hematology, 44(2):145–146
• [24] Hashmi, S.K., Srivastava, A., Rasheed, W., Adil, S., Wu, T., Jagasia, M., Nassar, A., Hwang, W.Y., Hamidieh, A.A., and Greinix, H.T. (2017). Cost and quality issues in establishing hematopoietic cell transplant program in developing countries. Hematology and Oncology Stem Cell Therapies, 10: 167–172
• [25] Heeney, M.M., Hoppe, C.C., Abboud, M.R., Inusa, B., Kanter, J., Ogutu, B., Brown, P.B., Heath, L.E., Jakubowski, J.A., and Zhou, C. (2016). A multi national trial of prasugrel for sickle cell vaso-occlusive events. Northern England Journal of Medicine, 374: 625–635
• [26] Hoppe, C.C., Styles, L., Heath, L.E., Zhou, C., Jakubowski, J.A., Winters, K.J., Brown, P.B., Rees, D.C., and Heeney, M.M. (2016). Design of the DOVE (Determining Effects of Platelet Inhibition on Vaso-Occlusive Events) trial: A global Phase 3 double-blind, randomized, placebo-controlled, multi center study of the efficacy and safety of prasugrel in pediatric patients with sickle cell anemia utilizing a dose titration strategy. Pediatric Blood Cancer, 63: 299–305
• [27] Ingram, V.M. (2004). Anecdotal, Historical and Critical Commentaries on Genetics Sickle-Cell Anemia Hemoglobin: The Molecular Biology of the First “Molecular Disease”—The Crucial Importance of Serendipity. Genetics, 167:1–7.
• [28] Kassim, A.A., and Sharma, D. (2017). Hematopoietic stem cell transplantation for sickle cell disease: The changing landscape. Hematology and Oncology Stem Cell Therapies, 10: 259–266
• [29] Kavanagh, P.L., Sprinz, P.G., Vinci, S.R., Bauchner, H., and Wang, C.J. (2011). Management of children with sickle cell disease: a comprehensive review of the literature. Pediatrics, 128(6): 1552–1574
• [30] Khatib, R., Rabah, R., and Sarnaik, S.A. (2009). The spleen in the sickling disorders: an update. Pediatric Radiology, 39(1): 17–22
• [31] Konothy, F.D. (2004). Effect of Environment on Sickle Cell Disease in West Africa; Epidemiological and Clinical Considerations: History and Origin. The Internet Journal of Hematology, 1(2).
• [32] Kumar, V., Abbas, A.K., Fausto, N., and Aster, J. (2009). Robbins and Cotran Pathologic Basis of Disease, Professional Edition: Expert Consult–Online (Robbins Pathology) (Kindle Locations 33498-33499). Elsevier Health, Kindle Edition.
• [33] Lee, C., Davies, S., and Dezatoux, C. (2000). Neonatal Screening for sickle cell disease. The Cochrane Collaboration. John Wiley & Sons, Ltd.
• [34] Mansour, A.K., Yahia, S., El-Ashry, R., Alwakeel, A., Darwish, A., and Alrjjal, K. (2015). Sickle Cell Disease (SCD). Inherited Hemoglobin Disorders, 35.
• [35] Mekontso, D.A., Leon, R., Habibi, A., Nzouakou, R., Roudot-Thoraval, F., Adnot, S., Godeau, B., Galacteros, F., Brun-Buisson, C., Brochard, L., and Maitre, B. (2008). Pulmonary hypertension and corpulmonale during severe acute chest syndrome in sickle cell disease. American Journal of Respiratory and Critical Care Medicine, 177(6): 646–653
• [36] Metcalf, B., Chuang, C., Dufu, K., Patel, M.P., Silva-Garcia, A., Johnson, C., Lu, Q., Partridge, J.R., Patskovska, L., and Patskovsky, Y. (2017). Discovery of GBT440, an orally bioavailable R-state stabilizer of sickle cell hemoglobin. ACS Medical Chemistry, 8: 321–326
• [37] Murad, M.H., Hazem, A., and Prokop, L. (2012). Hydroxyurea for Sickle Cell Disease: A Systematic Review of Benefits, Harms, and Barriers of Utilization, 2012 Prepared for the National Heart, Lung, and Blood Institute (NHLBI) Prepared by the Knowledge and Encounter Research Unit. Mayo Clinic, 1–116.
• [38] National Organization for Rare Disorders, (2019). Sickle Cell Disease. Retrieved 10 June 2019.
• [39] National Library of Medicine, (2016). URL=https://ghr.nlm.nih.gov/condition/sickle-celldisease#statistics. Archived 2016-05-15 at the Way back Machine.
• [40] National Heart, Lung and Blood Institute, (2010). Sickle cell anemia, key points. Archived from the original on 2010-12-02. Retrieved 2010-11-27.
• [41] Ndeezi, G., Kiyaga, C., Hernandez, A.G., Munube, D., Howard, T.A., Ssewanyana, I., Nsungwa, J., Kiguli, S., Ndugwa, C.M., Ware, R.E., and Jane, R. (2016). Burden of sickle cell trait and disease in the Uganda Sickle Surveillance Study (US3): across sectional study. The Lancet Global Health, 4(3): 195–200
• [42] Niihara, Y., Miller, S.T., Kanter, J., Lanzkron, S., Smith, W.R., Hsu, L.L., Gordeuk, V.R., Viswanathan, K., Sarnaik, S., Osunkwo, I., and Guillaume, E. (2018). A phase 3 trial of l-glutamine in sickle cell disease. Northern England Journal Medicine, 379: 226–235
• [43] Olujohungbe, A., and Burnett, A.L. (2013). How I manage priapism due to sickle cell disease. British Journal of Hematology, 160(6): 754–765
• [44] Paul, R.N., Castro, O.L., Aggarwal, A., and Oneal, P.A. (2011). Acute chest syndrome: sickle cell disease. European Journal of Haematology, 87(3): 191–207
• [45] Pearson, H.A. (1977). Sickle cell anemia and severe infections due to encapsulated bacteria. The Journal of Infectious Diseases, 136: 25–30
• [46] Piel, F.B., Steinberg, M.H., and Rees, D.C. (2017). Sickle Cell Disease. Northern England Journal of Medicine, 376: 1561–1573
• [47] Platt, O.S., Brambilla, D.J., and Rosse, W.F. (1994). Mortality in Sickle Cell Disease. Life Expectancy and Risk Factors for Early Death. Northern England Journal of Medicine, 330(23): 1639-1644
• [48] Powars, D.R., Elliott-Mills, D.D., Chan, L., Niland, J., Hiti, A.L., Opas, L.M., and Johnson, C. (1991). Chronic renal failure in sickle cell disease: risk factors, clinical course, and mortality. Annals of Internal Medicine, 115(8): 614–620
• [49] Reiter, C.D., Wang, X., Tanus-Santos, J.E., Hogg, N., Cannon, R.O., and Schechter, A.N. and Gladwin, M.T. (2002). Cell-free hemoglobin limits nitric oxide bioavailability in sickle-cell disease. Nature Medicine, 8(12): 1383-1389
• [50] Ribeil, J.A., Hacein-Bey-Abina, S., Payen, E., Magnani, A., Semeraro, M., Magrin, E., Caccavelli, L., Neven, B., Bourget, P., and ElNemer, W. (2017). Gene therapy in a patient with sickle cell disease. Northern England Journal of Medicine, 376: 848–855
• [51] Roberts, I., and de-Montalembert, M. (2007). Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe. Hematology, 92(7): 865–871
• [52] Sankaran, V.G., and Orkin, S.H. (2013). The switch from fetal to adult hemoglobin. Cold Spring Harbor Perspectives in Medicine, 3(1): 011643
• [53] Schmaier, A.H., and Lazarus, H.M. (2011). Concise guide to hematology. John Wiley and Sons, Ltd.
• [54] Setty, B.Y., Chen, D., and Stuart, M.J. (1996). Sickle red blood cells stimulate endothelial cell production of eicosanoids and diacylglycerol. Journal of Laboratory and Clinical Medicine, 128(3): 313-321
• [55] Slavov, S.N., Kashima, S., Pinto, A.C., and Covas, D.T. (2011). Human parvo virusB19: general considerations and impact on patients with sickle-cell disease and thalassemia and on blood transfusions. Immunology and Medical Microbiology, 62(3): 247–262
• [56] Steinberg, M.H. (2009). Genetic etiologies for phenotypic diversity in sickle cell anemia. Science World Journal, 9: 46–67
• [57] Steinberg, M.H., Barton, F., Castro, O., Pegelow, C.H., Ballas, S.K., Kutlar, A., Orringer, E., Bellevue, R., Olivieri, N., and Eckman, J. (2003). Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment. American Journal of Medical Anatomy, 289: 1645–1651
• [58] Suzanne, C. (2008). Genetic mutation. Nature Education, 1(1): 187
• [59] Telen, M.J. (2016). Beyond hydroxyurea: New and old drugs in the pipeline for sickle cell disease. Blood, 127: 810–819
• [60] Tusuubira, S.K., Nakayinga, R., Mwambi, B., Odda, J., Kiconco, S., and Komuhangi, A. (2018). Knowledge, perception and practices towards sickle cell disease: a community survey among adults in Lubaga division, Kampala Uganda. British Medical and Clinical Public Health, 18(1): 561
• [61] Ware, R.E. (2015). Optimizing hydroxyurea therapy for sickle cell anemia. ASH Education Program Book, 436–443
• [62] Weatherall, D.J., and Clegg, J.B. (2001). Inherited haemoglobin disorders: an increasing global health problem. Bulletin of the World Health Organization, 79(8): 704–712
• [63] Weatherall, D.J. (2010). The inherited diseases of hemoglobin are an emerging global health burden. Blood, 115: 4331–4336
• [64] Wellems, T.E., Hayton, K., and Fairhurst, R.M. (2009). The impact of malaria parasitism: from corpuscles to communities. The Journal of Clinical Investigation, 119(9): 2496–2505
• [65] Wellstein, A., and Pitschner, H.F. (1988). Complex dose-response curves of atropine in man explained by different functions of M1-and M2-cholinoceptors. Naunyn Schmiedeberg's Archives of Pharmacology, 338(1): 19–27
• [66] WHO, (2011). Sickle-cell anemia-Report by the Secretariat. Archived from the original (PDF) on 2011-01-04. Retrieved 2010-11-27
• [67] Wiebking, V., Hütker, S., Schmid, I., Immler, S., Feuchtinger, T., and Albert, M.H. (2017). Reduced toxicity, myelo ablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease. Annals Hematology, 96: 1373–1377
• [68] Wong, W.Y., Powars, D.R., Chan, L., Hiti, A., Johnson, C., and Overturf, G. (1992). Polysaccharide encapsulated bacterial infection in sickle cell anemia: a thirty year epidemiologic experience. American Journal of Hematology, 39(3): 176–182
• [69] Yawn, B. P., Buchanan, G. R., Afenyi-Annan, A. N., Ballas, S. K., Hassell, K. L., James, A. H., ... & John-Sowah, J. (2014). Management of sickle cell disease: summary of the 2014 evidence-based report by expert panel members. Jama, 312(10), 1033-1048

• Document Type: article